We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$349M
AUM Growth
+$53.4M
Cap. Flow
+$36.4M
Cap. Flow %
10.41%
Top 10 Hldgs %
7.12%
Holding
478
New
39
Increased
273
Reduced
76
Closed
38

Top Buys

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$2.36M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$1.99M
3
LRCX icon
Lam Research
LRCX
+$1.97M
4
IDXX icon
Idexx Laboratories
IDXX
+$1.96M
5
TKO icon
TKO Group
TKO
+$1.96M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.85M
2
KKR icon
KKR & Co
KKR
+$1.62M
3
UAL icon
United Airlines
UAL
+$1.62M
4
CBRE icon
CBRE Group
CBRE
+$1.61M
5
NU icon
Nu Holdings
NU
+$1.58M

Sector Composition

Rank Sector Weight
1 Financials 33.25%
2 Healthcare 17.27%
3 Technology 14.61%
4 Industrials 8.9%
5 Consumer Discretionary 5.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
176
Alnylam Pharmaceuticals
ALNY
$29.3B
$665K 0.19%
1,459
– –
MIRM icon
177
Mirum Pharmaceuticals
MIRM
$6.14B
$665K 0.19%
9,066
– –
INSM icon
178
Insmed
INSM
$28.6B
$661K 0.19%
4,587
– –
BKT icon
179
BlackRock Income Trust
BKT
$341M
$660K 0.19%
58,703
-2,049
-3% -$23.9K
ARDX icon
180
Ardelyx
ARDX
$997M
$658K 0.19%
119,461
– –
UTHR icon
181
United Therapeutics
UTHR
$23.1B
$651K 0.19%
1,553
– –
TARS icon
182
Tarsus Pharmaceuticals
TARS
$2.84B
$645K 0.18%
10,852
– –
ARCC icon
183
Ares Capital
ARCC
$14.4B
$622K 0.18%
30,499
-76
-0.2% -$1.69K
KNSA icon
184
Kiniksa Pharmaceuticals
KNSA
$5.93B
$622K 0.18%
16,026
– –
FSCO
185
FS Credit Opportunities Corp
FSCO
$1.02B
$619K 0.18%
+89,551
New +$656K
TSLX icon
186
Sixth Street Specialty
TSLX
$1.81B
$617K 0.18%
26,990
-2,312
-8% -$55.6K
TBPH icon
187
Theravance Biopharma
TBPH
$877M
$612K 0.18%
41,884
– –
HALO icon
188
Halozyme
HALO
$12.2B
$598K 0.17%
8,148
– –
AUPH icon
189
Aurinia Pharmaceuticals
AUPH
$2.11B
$597K 0.17%
53,997
– –
ROIV icon
190
Roivant Sciences
ROIV
$26.2B
$586K 0.17%
38,744
– –
BBIO icon
191
BridgeBio Pharma
BBIO
$16.5B
$582K 0.17%
11,208
– –
FOLD
192
DELISTED
Amicus Therapeutics
FOLD
$568K 0.16%
72,025
– –
KRYS icon
193
Krystal Biotech
KRYS
$9.66B
$559K 0.16%
3,167
– –
ONC
194
BeOne Medicines Ltd
ONC
$39.4B
$548K 0.16%
1,607
– –
INCY icon
195
Incyte
INCY
$24.4B
$544K 0.16%
6,420
-23,424
-78% -$1.85M
MRCC
196
DELISTED
Monroe Capital Corp
MRCC
$544K 0.16%
77,488
-4,804
-6% -$33K
NVAX icon
197
Novavax
NVAX
$1.31B
$539K 0.15%
62,153
– –
PTCT icon
198
PTC Therapeutics
PTCT
$6.12B
$535K 0.15%
8,717
– –
BCIC
199
BCP Investment Corp
BCIC
$92.9M
$529K 0.15%
45,852
+2,233
+5% +$27.5K
APLS
200
DELISTED
Apellis Pharmaceuticals
APLS
$522K 0.15%
23,073
– –
6 7
8
9 10

Similar funds

RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

Virtus Investment Advisers's Q3 2025 Portfolio in Review

As of Q3 2025, Virtus Investment Advisers held 478 positions worth $349M, up 18% from $296M the previous quarter. Its ten largest holdings account for 7.1% of the portfolio.

Virtus Investment Advisers deployed $36.4M of net new capital in Q3 2025, opening 39 new positions and adding to 273 existing holdings. Its largest new stake was Oxford Lane Capital: 129,209 shares worth $2.19M.

By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 33% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Incyte, an estimated $1.85M trimmed.

  • Virtus Investment Advisers's largest Q3 2025 buy was Oxford Lane Capital: 129,209 shares worth $2.19M.
  • Virtus Investment Advisers added most to Prospect Capital in Q3 2025, an estimated $697K increase.
  • Virtus Investment Advisers's biggest Q3 2025 reduction was Incyte, cutting an estimated $1.85M.
  • Virtus Investment Advisers fully exited KKR & Co in Q3 2025, selling an estimated $1.62M.
  • Virtus Investment Advisers's ten largest holdings make up 7.1% of its $349M portfolio in Q3 2025.
  • Virtus Investment Advisers opened 39 new positions and closed 38 in Q3 2025.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $349M.

Based on Virtus Investment Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.